NUCALA SOLUTION

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

MEPOLIZUMAB

Inapatikana kutoka:

GLAXOSMITHKLINE INC

ATC kanuni:

R03DX09

INN (Jina la Kimataifa):

MEPOLIZUMAB

Kipimo:

100MG

Dawa fomu:

SOLUTION

Tungo:

MEPOLIZUMAB 100MG

Njia ya uendeshaji:

SUBCUTANEOUS

Vitengo katika mfuko:

15G/50G

Dawa ya aina:

Prescription

Eneo la matibabu:

IMMUNOSUPPRESSIVE AGENTS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0157630001; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2019-10-08

Tabia za bidhaa

_ _
_ _
_ _
_ December 19, 2022_
_ _
_NUCALA, Mepolizumab _
_ Page 1 of 85_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
NUCALA
Mepolizumab for Injection
100 mg/mL lyophilized powder for subcutaneous injection
Mepolizumab Injection
100 mg/mL solution for subcutaneous injection
40 mg/0.4 mL solution for subcutaneous injection
Interleukin-5 (IL-5) inhibitor
GlaxoSmithKline Inc.
100 Milverton Drive
Suite 800
Mississauga, Ontario
L5R 4H1
Date of Initial Authorization:
DEC 03, 2015
Date of Revision:
NOV 28, 2023
Submission Control No: 270798
_©_
_2022 GSK group of companies of its licensor _
_Trademarks are owned by or licensed to the GSK group of companies _
_ _
_ _
_ _
_ December 19, 2022_
_ _
_NUCALA, Mepolizumab _
_ Page 2 of 85_
RECENT MAJOR LABEL CHANGES
SECTION
DATE
1 INDICATIONS
11/2021
4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations
09/2022
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose &
Dosage Adjustment
09/2022
4 DOSAGE AND ADMINISTRATION, 4.4 Administration
09/2022
4 DOSAGE AND ADMINISTRATION, 4.5 Missed Dose
09/2022
7 WARNINGS AND PRECAUTIONS, 7.1 Special Populations
11/2021
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women
11/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.........................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION ................................................................................
4
1
INDICATIONS ......................................................................................................................
4
1.1 Pediatrics
..................................................................................................................................
4
1.2 Geriatrics
...............................................................................